Loading...
Header Logo
Keywords
Last Name
Institution

NUHAD K IBRAHIM

TitleProfessor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JP, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin Cancer Res. 2019 Mar 13. PMID: 30867218.
      View in: PubMed
    2. Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 Mar 12; JCO1801511. PMID: 30860945.
      View in: PubMed
    3. Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer. 2018 12 01; 143(11):3019-3026. PMID: 29923182.
      View in: PubMed
    4. Al-Awadhi A, Lee Murray J, Ibrahim NK. Developing anti-HER2 vaccines: Breast cancer experience. Int J Cancer. 2018 11 01; 143(9):2126-2132. PMID: 29693245.
      View in: PubMed
    5. Weiss A, Bashour SI, Hess K, Thompson AM, Ibrahim NK. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. Breast Cancer Res. 2018 04 16; 20(1):27. PMID: 29661243.
      View in: PubMed
    6. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 Jun 01; 124(11):2299-2305. PMID: 29579338.
      View in: PubMed
    7. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017; 8(11):2004-2009. PMID: 28819400.
      View in: PubMed
    8. Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun. 2017 06 27; 8:15916. PMID: 28653662.
      View in: PubMed
    9. Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC. Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Oncologist. 2017 05; 22(5):526-534. PMID: 28377466.
      View in: PubMed
    10. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515. PMID: 27893038.
      View in: PubMed
    11. Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA. Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients. Ann Surg Oncol. 2017 Aug; 24(8):2161-2167. PMID: 28315060.
      View in: PubMed
    12. Sneige N, Hess KR, Multani AS, Gong Y, Ibrahim NK. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer. 2017 04 01; 123(7):1115-1123. PMID: 27893937.
      View in: PubMed
    13. Farsaci B, Donahue RN, Grenga I, Lepone LM, Kim PS, Dempsey B, Siebert JC, Ibrahim NK, Madan RA, Heery CR, Gulley JL, Schlom J. Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunol Res. 2016 09 02; 4(9):755-65. PMID: 27485137.
      View in: PubMed
    14. Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat. 2016 07; 158(1):67-77. PMID: 27287781.
      View in: PubMed
    15. Mitri Z, Nanda R, Blackwell K, Costelloe CM, Hood I, Wei C, Brewster AM, Ibrahim NK, Koenig KB, Hortobagyi GN, Van Poznak C, Rimawi MF, Moulder-Thompson S. TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. Clin Cancer Res. 2016 Dec 01; 22(23):5706-5712. PMID: 27166393.
      View in: PubMed
    16. Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52. PMID: 26834058.
      View in: PubMed
    17. Raghav K, French JT, Ueno NT, Lei X, Krishnamurthy S, Reuben JM, Valero V, Ibrahim NK. Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction. PLoS One. 2016; 11(1):e0145534. PMID: 26752563.
      View in: PubMed
    18. Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, McMahon S, Marté JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio LR, Schlom J, Gulley JL. Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2015 Nov; 1(8):1087-95. PMID: 26291768.
      View in: PubMed
    19. Delpech Y, Bashour SI, Lousquy R, Rouzier R, Hess K, Coutant C, Barranger E, Esteva FJ, Ueno NT, Pusztai L, Ibrahim NK. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. Br J Cancer. 2015 Sep 29; 113(7):1003-9. PMID: 26393887.
      View in: PubMed
    20. Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT. Cancer. 2015 Nov 15; 121(22):3965-74. PMID: 26249241.
      View in: PubMed
    21. Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs. 2015 Aug; 33(4):890-4. PMID: 25947565.
      View in: PubMed
    22. Bashour SI, Ibrahim NK. CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel-How Far Science Has Come. Clin Cancer Res. 2015 May 01; 21(9):1975-7. PMID: 25934886.
      View in: PubMed
    23. Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer. 2015 Oct; 15(5):325-31. PMID: 25913905; PMCID: PMC4568133 [Available on 10/01/16].
    24. Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist. 2015 May; 20(5):466-73. PMID: 25802405.
      View in: PubMed
    25. Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK. Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. J Cancer. 2014; 5(5):351-9. PMID: 24723978; PMCID: PMC3982182.
    26. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. Ann Oncol. 2014 Jun; 25(6):1122-7. PMID: 24669015; PMCID: PMC4037860.
    27. Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, Miles D. Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial. J Cancer. 2013; 4(7):577-84. PMID: 23983823; PMCID: PMC3753533.
    28. Yust-Katz S, Garciarena P, Liu D, Yuan Y, Ibrahim N, Yerushalmi R, Penas-Prado M, Groves MD. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol. 2013 Sep; 114(2):229-35. PMID: 23756727.
      View in: PubMed
    29. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis. 2013 Jun; 30(5):631-42. PMID: 23370825; PMCID: PMC3857726.
    30. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):631-6. PMID: 23242617; PMCID: PMC3867793.
    31. Song W, Delyria ES, Chen J, Huang W, Lee JS, Mittendorf EA, Ibrahim N, Radvanyi LG, Li Y, Lu H, Xu H, Shi Y, Wang LX, Ross JA, Rodrigues SP, Almeida IC, Yang X, Qu J, Schocker NS, Michael K, Zhou D. MUC1 glycopeptide epitopes predicted by computational glycomics. Int J Oncol. 2012 Dec; 41(6):1977-84. PMID: 23023583; PMCID: PMC3556481.
    32. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5. PMID: 22331946.
      View in: PubMed
    33. Ibrahim N, Yu Y, Walsh WR, Yang JL. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep. 2012 May; 27(5):1303-11. PMID: 22323095.
      View in: PubMed
    34. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34. PMID: 22042783; PMCID: PMC3233286.
    35. Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011 Nov 01; 17(21):6905-13. PMID: 22028489.
      View in: PubMed
    36. Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, Ibrahim NK. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2011 Nov 01; 17(21):6888-96. PMID: 21989064.
      View in: PubMed
    37. Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Erlandsson F, Acton G, Pegram M. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res. 2011 Nov 01; 17(21):6822-30. PMID: 21878535.
      View in: PubMed
    38. Zhou D, Levery SB, Hsu FF, Wang PG, Teneberg S, Almeida IC, Li Y, Xu H, Wang LX, Xia C, Ibrahim NK, Michael K. Immunologic mapping of glycomes: implications for cancer diagnosis and therapy. Front Biosci (Schol Ed). 2011 Jun 01; 3:1520-32. PMID: 21622287; PMCID: PMC3548420.
    39. Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011; 16(8):1092-100. PMID: 21572124; PMCID: PMC3228158.
    40. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81. PMID: 21558518.
      View in: PubMed
    41. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010 Nov 01; 16(21):5351-61. PMID: 20829329; PMCID: PMC4181852.
    42. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol. 2010 Oct 01; 28(28):4316-23. PMID: 20805453.
      View in: PubMed
    43. Ibrahim NK. Ixabepilone development across the breast cancer continuum: a paradigm shift. Cancer Manag Res. 2010 Jun 30; 2:169-79. PMID: 21188108; PMCID: PMC3004591.
    44. Hortobagyi GN, Young RR, Karwal M, Ibrahim NK, Hermann R, Murray JL, Watkins SP, Gore I. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer. 2010 May 15; 116(10):2301-6. PMID: 20225231.
      View in: PubMed
    45. Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R, Ibrahim NK. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol. 2010 Apr 20; 28(12):2032-7. PMID: 20308667.
      View in: PubMed
    46. Royer B, Yin W, Pegram M, Ibrahim N, Villanueva C, Mir D, Erlandsson F, Pivot X. Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. Br J Cancer. 2010 Mar 02; 102(5):827-32. PMID: 20160731; PMCID: PMC2833251.
    47. Ibrahim NK, Abalkhail B, Rady M, Al-Bar H. An educational programme on dengue fever prevention and control for females in Jeddah high schools. East Mediterr Health J. 2009 Sep-Oct; 15(5):1058-67. PMID: 20214118.
      View in: PubMed
    48. Estephan F, Valero V, Esteva FJ, Mejia JA, Frye DK, Ibrahim NK. Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule. Oncology. 2009; 77(1):63-70. PMID: 19556811.
      View in: PubMed
    49. Ibrahim NK, Al Bar HM. Surveillance of childhood vaccine-preventable diseases at health facilities in Jeddah, Saudi Arabia. East Mediterr Health J. 2009 May-Jun; 15(3):532-43. PMID: 19731769.
      View in: PubMed
    50. Sallam SA, Khallafallah NM, Ibrahim NK, Okasha AO. Pharmacoepidemiological study of self-medication in adults attending pharmacies in Alexandria, Egypt. East Mediterr Health J. 2009 May-Jun; 15(3):683-91. PMID: 19731784.
      View in: PubMed
    51. Ibrahim NK, Al Ashakar MS, Gad ZM, Warda MH, Ghanem H. An epidemiological study on survival of oropharyngeal cancer cases in Alexandria, Egypt. East Mediterr Health J. 2009 Mar-Apr; 15(2):369-77. PMID: 19554984.
      View in: PubMed
    52. Shumway NM, Ibrahim N, Ponniah S, Peoples GE, Murray JL. Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs. 2009; 23(5):277-87. PMID: 19754218.
      View in: PubMed
    53. Pegram MD, Borges VF, Ibrahim N, Fuloria J, Shapiro C, Perez S, Wang K, Schaedli Stark F, Courtenay Luck N. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009; 11(5):R73. PMID: 19811637; PMCID: PMC2790853.
    54. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 2008 Jul; 19(7):1242-8. PMID: 18334512.
      View in: PubMed
    55. Kaur H, Loyer EM, David CL, Sawaf H, DuBrow RA, Ibrahim NK. Radiologic findings in taxane induced colitis. Eur J Radiol. 2008 Apr; 66(1):75-8. PMID: 17553645.
      View in: PubMed
    56. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 01; 13(1):228-33. PMID: 17200359.
      View in: PubMed
    57. Pinder MC, Ibrahim NK. Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer. Drugs Today (Barc). 2006 Sep; 42(9):599-604. PMID: 17028669.
      View in: PubMed
    58. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10; 24(26):4236-44. PMID: 16896004.
      View in: PubMed
    59. Motwani SB, Strom EA, Schechter NR, Butler CE, Lee GK, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Ibrahim NK, Buchholz TA. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Sep 01; 66(1):76-82. PMID: 16765534.
      View in: PubMed
    60. Altundag K, Ibrahim NK. Aromatase inhibitors in breast cancer: an overview. Oncologist. 2006 Jun; 11(6):553-62. PMID: 16794235.
      View in: PubMed
    61. Davidson N, Ibrahim N, Harries M, Harper P. Albumin-bound Paclitaxel in metastatic breast cancer: viewpoints. Drugs. 2006; 66(7):949-50. PMID: 16740011.
      View in: PubMed
    62. Chedid S, Rivera E, Frye DK, Ibrahim N, Esteva F, Valero V, Hortobagyi G, Mettinger KL, Cristofanilli M. Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2006 Apr; 57(4):540-4. PMID: 16193332.
      View in: PubMed
    63. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005 Sep 01; 23(25):6019-26. PMID: 16135470.
      View in: PubMed
    64. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005 Aug 15; 104(4):682-91. PMID: 15986399.
      View in: PubMed
    65. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15; 11(16):5678-85. PMID: 16115903.
      View in: PubMed
    66. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 01; 23(25):5983-92. PMID: 16087943.
      View in: PubMed
    67. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85. PMID: 15738535.
      View in: PubMed
    68. Ibrahim NK. Leukemogenic effect of chemotherapy in patients with breast carcinoma: is it a real concern? Cancer. 2004 Oct 01; 101(7):1479-81. PMID: 15378475.
      View in: PubMed
    69. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer. 2004 Oct 01; 101(7):1508-13. PMID: 15378497.
      View in: PubMed
    70. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93. PMID: 15136595.
      View in: PubMed
    71. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 07; 25(3):94-102. PMID: 14698135.
      View in: PubMed
    72. Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res. 2003 Jul; 9(7):2426-34. PMID: 12855614.
      View in: PubMed
    73. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003 Jun 15; 97(12):2960-71. PMID: 12784330.
      View in: PubMed
    74. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 Mar 15; 21(6):1167-73. PMID: 12637486.
      View in: PubMed
    75. Ibrahim NK, Murray JL. Clinical development of the STn-KLH vaccine (Theratope). Clin Breast Cancer. 2003 Feb; 3 Suppl 4:S139-43. PMID: 12620151.
      View in: PubMed
    76. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 2002 Nov; 8(11):3360-8. PMID: 12429622.
      View in: PubMed
    77. Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2002 Nov; 8(11):3407-18. PMID: 12429628.
      View in: PubMed
    78. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9. PMID: 12006521.
      View in: PubMed
    79. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002 May; 8(5):1038-44. PMID: 12006516.
      View in: PubMed
    80. Esmaeli B, Hortobagyi G, Esteva F, Valero V, Ahmadi MA, Booser D, Ibrahim N, Delpassand E, Arbuckle R. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol. 2002 Feb; 13(2):218-21. PMID: 11885997.
      View in: PubMed
    81. Ibrahim NK, Rahman Z, Valero V, Murray JL, Frye D, Hortobagyi GN. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. Cancer Invest. 2002; 20(1):29-37. PMID: 11852999.
      View in: PubMed
    82. Ibrahim NK. Commentary on "A review of vinorelbine in the treatment of breast cancer". Clin Breast Cancer. 2001 Oct; 2(3):236. PMID: 11899419.
      View in: PubMed
    83. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82. PMID: 11745249.
      View in: PubMed
    84. Sulkes A, Stemmer SM. Doxorubicin-based chemotherapy in the elderly. Ann Oncol. 2001 Aug; 12(8):1180-1. PMID: 11583205.
      View in: PubMed
    85. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33. PMID: 11454891.
      View in: PubMed
    86. Ibrahim NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer. 2001 Feb 15; 91(4):664-71. PMID: 11241232.
      View in: PubMed
    87. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66. PMID: 11458813.
      View in: PubMed
    88. Ibrahim NK, Buzdar AU, Asmar L, Theriault RL, Hortobagyi GN. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol. 2000 Dec; 11(12):1597-601. PMID: 11205469.
      View in: PubMed
    89. Sezer O, Eucker J, Possinger K. Colitis associated with docetaxel-based chemotherapy. Lancet. 2000 May 20; 355(9217):1823-4. PMID: 10832856.
      View in: PubMed
    90. Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU, Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21. PMID: 10776969.
      View in: PubMed
    91. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, Buzdar AU, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000 Jan 22; 355(9200):281-3. PMID: 10675076.
      View in: PubMed
    92. Edeiken BS, Fornage BD, Bedi DG, Singletary SE, Ibrahim NK, Strom EA, Holmes F. US-guided implantation of metallic markers for permanent localization of the tumor bed in patients with breast cancer who undergo preoperative chemotherapy. Radiology. 1999 Dec; 213(3):895-900. PMID: 10580972.
      View in: PubMed
    93. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7. PMID: 10550135.
      View in: PubMed
    94. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, Bast R, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer. 1999 Oct 01; 86(7):1251-7. PMID: 10506711.
      View in: PubMed
    95. Ibrahim NK, Hortobagyi GN. The evolving role of specific estrogen receptor modulators (SERMs) Surg Oncol. 1999 Aug; 8(2):103-23. PMID: 10732962.
      View in: PubMed
    96. Ibrahim NK, Hortobagyi GN, Ewer M, Ali MK, Asmar L, Theriault RL, Fraschini G, Frye DK, Buzdar AU. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol. 1999; 43(6):471-8. PMID: 10321507.
      View in: PubMed
    97. Le Chevalier T, Monnier A, Douillard JY, Ruffie P, Sun XS, Belli L, Ibrahim N, Bougon N, Bérille J. Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer. 1998 Dec; 34(13):2032-6. PMID: 10070306.
      View in: PubMed
    98. Rosner F. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998 Sep 01; 83(5):1054-5. PMID: 9731914.
      View in: PubMed
    99. Ibrahim NK, Hortobagyi GN. New antiestrogens in breast cancer: a review. Breast J. 1998 Jul; 4(4):213-29. PMID: 21223440.
      View in: PubMed
    100. Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 1998 Apr 23; 16(16):2087-94. PMID: 9572489.
      View in: PubMed
    101. Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998 Mar 01; 82(5):965-9. PMID: 9486588.
      View in: PubMed
    102. Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, Buzdar AU. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 3):S30-3. PMID: 9071338.
      View in: PubMed
    103. Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996 Apr 22; 156(8):882-8. PMID: 8774207.
      View in: PubMed
    104. Hortobagyi GN, Ibrahim N. Paclitaxel-containing combination chemotherapy for metastatic breast cancer. Semin Oncol. 1996 Feb; 23(1 Suppl 1):53-7. PMID: 8629039.
      View in: PubMed
    105. Ibrahim NK, Buzdar AU. Aromatase inhibitors: current status. Am J Clin Oncol. 1995 Oct; 18(5):407-17. PMID: 7572758.
      View in: PubMed
    106. Tsai CM, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK, Hung MC. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst. 1995 May 03; 87(9):682-4. PMID: 7538595.
      View in: PubMed
    107. Ibrahim NK, Khouri FP, Salem PA. VP-16-based regimen in adult acute nonlymphoblastic leukemia. Oncology. 1988; 45(1):21-3. PMID: 3340391.
      View in: PubMed
    108. Ibrahim NK, Abdul-Karim FW. Colorectal adenocarcinoma in young Lebanese adults. The American University of Beirut-Medical Center experience with 32 patients. Cancer. 1986 Aug 01; 58(3):816-20. PMID: 3015371.
      View in: PubMed
    109. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment. 158:67-77.
    110. Albumin-bound paclitaxel in metastatic breast cancer. Drugs. 66:950.
    111. Brain Metastasis from Solid Tumors. 3-29.
    112. Breast cancer in the elderly. Cancer Bulletin. 47:212-217.
    113. Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors. Breast Diseases. 24:224-225.
    114. Phase II Randomized Study of Ixabepilone Versus Observation in Patients with Significant Residual Disease after Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clinical Breast Cancer. 15:325-331.
    115. TBCRC-010. Clinical Cancer Research. 22:5706-5712.
    116. Herceptin plus chemotherapy combination in preoperative regimen may offer clinical benefit in early stage breast cancer. Cancer Biology and Therapy. 4.
    117. Combinations of new and old agents for breast cancer treatment. Oncology. 10:30-36.
    118. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Investigational New Drugs.
    119. Brachial plexopathy and porencephaly in a patient with breast cancer. Cancer Bulletin. 46:185-188.
    120. Risk stratification in patients with advanced-stage breast cancer by pretreatment [<sup>18</sup>F]FDG PET/CT. Cancer.
    121. Ixabepilone development across the breast cancer continuum. Cancer Management and Research. 2:169-179.
    122. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Seminars in Oncology. 24.
    123. Glutathione S-transferase-pi expression in prechemotherapy and postchemotherapy tumor samples from patients with locally advanced breast carcinomas. Breast Journal. 2:246-252.
    124. A preoperative nomogram to predict the risk of synchronous distant metastases at diagnosis of primary breast cancer. Breast Diseases. 26:317-319.
    125. The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better. Translational Cancer Research. 5:S694-S696.
    126. Breast cancer with brainmetastases. Oncologist. 20:466-473.
    127. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer. Cancer.
    128. BAVITUXIMAB. Drugs of the Future. 40:281-286.
    129. Inflammatory breast cancer. PLoS One. 11.
    130. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Women's Oncology Review. 4:211-212.
    131. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. British Journal of Cancer. 113:1003-1009.
    IBRAHIM's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description